SavedAdd your journal

Journals / European Archives of Medical Research / 2019 / Cilt: 35 - Sayı: 1

The Effect of Pre-treatment Intraretinal Cyst Diameter on Visual and Anatomical Outcomes after Intravitreal Ranibizumab Treatment in Cystoid Macular Edema Secondary to Branch Retinal Vein Occlusion

Akın ÇAKIR
Şeyma GÜLCENUR ŞEHİRLİ
Burak ERDEN
Selim BÖLÜKBAŞI
Alper Halil BAYAT
Mustafa Nuri ELÇİOĞLU
Pages
11–14
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although there was a low degree negative correlationbetween pre-treatment cyst diameter and BCVA, this correlation was not statistically significant (r=-0.145, p=0.184).Conclusion: There was no statistically significant correlation between pre-treatment cyst diameter and CMT and BCVA gain in CME treatmentsecondary to BRVO.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the effect of the largest intraretinal cyst diameter in the macula on visual and anatomical outcomes after intravitrealranibizumab (IVR) treatment in cystoid macular edema (CME) secondary to branch retinal vein occlusion (BRVO).Methods: Forty-two eyes of 42 patients who underwent IVR treatment for CME secondary to BRVO were studied retrospectively.
📊
Key Findings & Data:The effect of pre-treatment intraretinal cyst diameter on post-treatment central macular thickness(CMT) and BCVA was investigated.Results: There were 27 (64.3%) men and 15 (35.7%) women in the study.
💡
Conclusion & Impact:Although there was a low degree negative correlationbetween pre-treatment cyst diameter and BCVA, this correlation was not statistically significant (r=-0.145, p=0.184).Conclusion: There was no statistically significant correlation between pre-treatment cyst diameter and CMT and BCVA gain in CME treatmentsecondary to BRVO.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the effect of the largest intraretinal cyst diameter in the macula on visual and anatomical outcomes after intravitrealranibizumab (IVR) treatment in cystoid macular edema (CME) secondary to branch retinal vein occlusion (BRVO).Methods: Forty-two eyes of 42 patients who underwent IVR treatment for CME secondary to BRVO were studied retrospectively. Patients wereevaluated after three-monthly IVR injection. The pre-treatment and post-treatment spectral domain optical coherence tomography parameters andbest-corrected visual acuity (BCVA) were recorded. The effect of pre-treatment intraretinal cyst diameter on post-treatment central macular thickness(CMT) and BCVA was investigated.Results: There were 27 (64.3%) men and 15 (35.7%) women in the study. The mean age was 59.5±9.6 years. The mean pre-treatment CMT was485±160 μm and the mean pre-treatment BCVA was 0.84±0.55 logMAR. After 3 doses of IVR, CMT gain was 201±168 μm and BCVA gain was 0.41±0.43logMAR. The mean pre-treatment cyst diameter was 241±121 μm. Although there was a low degree positive correlation between pre-treatment cystdiameter and CMT gain, this correlation was not statistically significant (r=0.245, p=0.059). Although there was a low degree negative correlationbetween pre-treatment cyst diameter and BCVA, this correlation was not statistically significant (r=-0.145, p=0.184).Conclusion: There was no statistically significant correlation between pre-treatment cyst diameter and CMT and BCVA gain in CME treatmentsecondary to BRVO.

🔖

Cite This Article

ÇAKIR, A., ŞEHİRLİ, Ş. G., ERDEN, B., BÖLÜKBAŞI, S., BAYAT, A. H., ELÇİOĞLU, M. N. (2022). The Effect of Pre-treatment Intraretinal Cyst Diameter on Visual and Anatomical Outcomes after Intravitreal Ranibizumab Treatment in Cystoid Macular Edema Secondary to Branch Retinal Vein Occlusion. European Archives of Medical Research, Cilt: 35 - Sayı: 1, 11–14. https://ajindex.com/articles/510441

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-9
  2. Jaulim A, Ahmed B, Chatziralli IP. Branch Retinal Vein Occlusion: Epidemiology, Pathogenesis, Risk Factors, Clinical Features, Diagnosis, And Complications. An Update Of The Literature. Retina 2013;33:901-10
  3. Son BK, Kwak HW, Kim ES, Yu SY. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion. Korean J Ophthalmol 2017;31:209-216
  4. Cruz N, Pinilla I, Casas P. et al. Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion. Acta Ophthalmologica 2010;88.0
  5. Moon BG, Cho AR, Kim YN, Kim JG. Predictors Of Refractory Macular Edema After Branch Retinal Vein Occlusion Following Intravitreal Bevacizumab. Retina 2017;0:1-9
  6. Mylonas G, Sacu S, Dunavoelgyi R. Response Of Retinal Sensivity To Ranibizumab Treatment Of Macular Edema After Acute Branch Retinal Vein Occlusion. Retina 2013;33.6:1220-6
  7. Korobelnik JF, Kodjikian L, Delcourt C, Gualino V7, Leaback R, Pinchinat S, et al. Two-Year, Prospective, Multicenter Study Of The Use Of Dexamethasone Intravitreal Implant For Treatment Of Macular Edema Secondary To Retinal Vein Occlusion In The Clinical Setting In France. Graefes Arch Clin Exp Ophthalmol 2016;254:2307-18
  8. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab For Macular Edema Following Branch Retinal Vein Occlusion: Six-Month Primary End Point Results Of A Phase III Study. Ophthalmology 2010;117:1102-12
  9. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, et al. Sustained Benefits From Ranibizumab For Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes Of A Phase III Study. Ophthalmology 2011;118:1594-602
  10. Minami Y, Nagaoka T, Ishibazawa A, Yoshida A. Short-Term Effect Of Intravitreal Ranibizumab Therapy On Macular Edema After Branch Retinal Vein Occlusion. Retina 2016;36:1726-32
  11. Sophie R, Hafiz G, Scott AW, Zimmer-Galler I, Nguyen QD, Ying H, et al. Long-Term Outcomes In Ranibizumab-Treated Patients With Retinal Vein Occlusion; The Role Of Progression Of Retinal Nonperfusion. Am J Ophthalmol 2013;156:693-705
  12. Brynskov T, Kemp H, Sorensen TL. Intravitreal Ranibizumab For Retinal Vein Occlusion Through 1 Year In Clinical Practice. Retina 2014;34:1637-43
  13. Jaissle GB,